ESSA Pharma Inc.·4

Feb 7, 11:29 AM ET

Virsik Peter 4

4 · ESSA Pharma Inc. · Filed Feb 7, 2024

Insider Transaction Report

Form 4
Period: 2024-02-06
Virsik Peter
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Shares

    2024-02-06$3.23/sh+72,782$235,08686,110 total
  • Sale

    Common Shares

    2024-02-06$10.29/sh72,782$748,92713,328 total
  • Exercise/Conversion

    Options

    2024-02-0672,782895,000 total
    Exercise: $3.23From: 2023-10-07Exp: 2029-10-07Common Shares (72,782 underlying)
Footnotes (2)
  • [F1]Reflects a transaction effected pursuant to Mr. Virsik's 10b5-1 trading plan. The Rule 10b5-1 trading plan was entered into on August 31, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION